Research Analysts Set Expectations for Zoetis Q2 Earnings

Zoetis Inc. (NYSE:ZTS) – Research analysts at Leerink Partnrs upped their Q2 2025 earnings estimates for Zoetis in a report issued on Thursday, July 17th. Leerink Partnrs analyst D. Clark now expects that the company will post earnings of $1.61 per share for the quarter, up from their previous forecast of $1.60. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Zoetis’ current full-year earnings is $6.07 per share. Leerink Partnrs also issued estimates for Zoetis’ FY2026 earnings at $6.81 EPS, FY2027 earnings at $7.26 EPS and FY2028 earnings at $7.73 EPS.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The company had revenue of $2.22 billion during the quarter, compared to analysts’ expectations of $2.20 billion. During the same quarter in the previous year, the company earned $1.38 earnings per share. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis.

Other equities analysts also recently issued reports about the company. Piper Sandler raised their price objective on Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a research note on Monday, May 12th. UBS Group reduced their target price on Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, May 7th. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Finally, Stifel Nicolaus downgraded Zoetis from a “buy” rating to a “hold” rating and reduced their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $204.63.

Zoetis Price Performance

ZTS stock opened at $147.31 on Monday. The business’s 50-day moving average is $160.77 and its two-hundred day moving average is $161.42. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.74 and a quick ratio of 1.04. The firm has a market capitalization of $65.59 billion, a P/E ratio of 24.68, a P/E/G ratio of 2.46 and a beta of 0.91. Zoetis has a 1 year low of $139.70 and a 1 year high of $200.33.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.36%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis’s payout ratio is presently 35.91%.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president directly owned 15,129 shares of the company’s stock, valued at $2,571,930. This represents a 4.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by company insiders.

Hedge Funds Weigh In On Zoetis

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Nova Wealth Management Inc. bought a new stake in Zoetis during the first quarter worth $25,000. 1248 Management LLC bought a new stake in Zoetis in the first quarter worth about $27,000. Saudi Central Bank purchased a new position in Zoetis in the first quarter valued at approximately $29,000. Navigoe LLC bought a new position in shares of Zoetis during the 4th quarter worth $30,000. Finally, Cornerstone Planning Group LLC increased its stake in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after purchasing an additional 88 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.